Deutsche Bank AG lowered its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 376,285 shares of the specialty pharmaceutical company’s stock after selling 19,989 shares during the quarter. Deutsche Bank AG’s holdings in Paratek Pharmaceuticals were worth $6,734,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Allianz Asset Management GmbH grew its position in Paratek Pharmaceuticals by 6.0% during the third quarter. Allianz Asset Management GmbH now owns 65,366 shares of the specialty pharmaceutical company’s stock worth $1,641,000 after buying an additional 3,719 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in Paratek Pharmaceuticals during the third quarter worth approximately $104,000. SG Americas Securities LLC acquired a new stake in Paratek Pharmaceuticals during the third quarter worth approximately $123,000. Geode Capital Management LLC grew its position in Paratek Pharmaceuticals by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 200,782 shares of the specialty pharmaceutical company’s stock worth $3,593,000 after buying an additional 5,151 shares in the last quarter. Finally, Sei Investments Co. grew its position in Paratek Pharmaceuticals by 2,069.3% during the third quarter. Sei Investments Co. now owns 8,981 shares of the specialty pharmaceutical company’s stock worth $225,000 after buying an additional 8,567 shares in the last quarter. 74.44% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on PRTK. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday, January 10th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. UBS downgraded Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Friday, March 2nd. Leerink Swann reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Sunday, March 4th. Finally, ValuEngine downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.00.
In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 16,291 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $14.22, for a total value of $231,658.02. Following the sale, the chief financial officer now owns 39,570 shares of the company’s stock, valued at approximately $562,685.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Adam Woodrow sold 14,333 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $13.87, for a total value of $198,798.71. Following the completion of the sale, the vice president now directly owns 62,367 shares in the company, valued at approximately $865,030.29. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,664 shares of company stock worth $573,226. Company insiders own 4.90% of the company’s stock.
Shares of PRTK stock opened at $13.05 on Monday. The firm has a market capitalization of $410.33, a price-to-earnings ratio of -3.95 and a beta of 0.43. Paratek Pharmaceuticals Inc has a fifty-two week low of $11.85 and a fifty-two week high of $29.00. The company has a debt-to-equity ratio of 0.72, a quick ratio of 9.56 and a current ratio of 9.56.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.03). The business had revenue of $5.07 million during the quarter, compared to analyst estimates of $5.00 million. Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. analysts forecast that Paratek Pharmaceuticals Inc will post -3.44 earnings per share for the current year.
WARNING: “Deutsche Bank AG Sells 19,989 Shares of Paratek Pharmaceuticals Inc (PRTK)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/09/deutsche-bank-ag-sells-19989-shares-of-paratek-pharmaceuticals-inc-prtk.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.